A potential immunological silver bullet for COVID‐19: The trivalent chimpanzee adenoviral serotype‐68 vector (Tri:ChAd)
Abstract
No abstract availableKeywords
All Related Versions
This publication has 8 references indexed in Scilit:
- Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2Cell, 2022
- COVID-19 vaccines for childrenScience, 2021
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19New England Journal of Medicine, 2021
- EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccinesAllergy, 2021
- Lessons for COVID-19 Immunity from Other Coronavirus InfectionsImmunity, 2020
- Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19Allergy, 2020
- Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, ChinaAllergy, 2020
- Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trialThe Lancet Infectious Diseases, 2014